No Data
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Multiple bullish factors boost pharmaceutical stocks listed in Hong Kong, institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Hong Kong stocks anomalies | Medical device stocks rise, medical insurance prepayments expected to accelerate enterprise receivables, innovative devices will usher in a new volume of space.
Most medical instruments stocks are rising. As of the time of publication, Microport (00853) is up 5.01% at 6.92 Hong Kong dollars; Sh Pharma (02607) is up 4.05% at 13.36 Hong Kong dollars; Sinopharm (01099) is up 3.14% at 21.35 Hong Kong dollars.
Major rating | Citigroup: Downgrade Shanghai Pharmaceuticals' target price to HK$15.3, maintain a "buy" rating.
Gelonghui November 12th | Citigroup's research report stated that sh pharma's third-quarter revenue increased by 8% year-on-year to 70 billion yuan, affected by a decrease in gross margin, net profit fell by 6% year-on-year to 1.1 billion yuan, with a gross margin of 10% during the period, compared to 10.6% in the same period of the previous fiscal year. The company's management expects to obtain approval for one innovative drug next year. It is expected that traditional chinese medicine Weifuchun will achieve sales of 1 billion yuan next year, and the other four traditional chinese medicine products will generate revenue of 0.1 billion yuan each. The bank has lowered its earnings forecast per share for each year from 2024 to 2026 by 6%, 5%, and 5% respectively, to reflect the challenges faced by pharmacies and the narrowing profit margins of distribution business.
Citigroup: Maintains a "buy" rating on Sh Pharma (02607) with a target price lowered to 15.3 Hong Kong dollars
Citi lowered sh pharma's earnings forecasts per share for the years 2024 to 2026 by 6%, 5%, and 5% respectively.
Citi reduced the target price of Sh Pharma (02607.HK) to 15.3 yuan in the third quarter, net profit decreased due to a drop in gross margin.
Citigroup's research report stated that sh pharma (02607.HK) saw a 8% year-on-year increase in third-quarter revenue to 70 billion RMB (same below), with a decline in gross margin, net profit dropping by 6% year-on-year to 1.1 billion RMB, and gross margin falling to 10% during the period, compared to 10.6% in the same period of the previous fiscal year. The company's management expects to obtain approval for an innovative drug next year, with sales of traditional Chinese medicine 'Wei Fuchun' expected to reach 1 billion RMB next year, and the other four traditional Chinese medicine products generating 0.1 billion RMB income each. The bank has lowered its earnings forecasts per share for each year from 2024 to 2026 by 6%, 5%, and 5%, respectively, to reflect challenges facing the pharmaceutical industry, as well as.
No Data
No Data